{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T03:03:06Z","timestamp":1793674986784,"version":"4.5.1"},"reference-count":51,"publisher":"American Society of Hematology","issue":"17","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,9,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Graft-versus-host disease (GVHD) of the gastrointestinal (GI) tract is the main cause of nonrelapse mortality (NRM) after allogeneic hematopoietic cell transplantation. Ann Arbor (AA) scores derived from serum biomarkers at onset of GVHD quantify GI crypt damage; AA2\/3 scores correlate with resistance to treatment and higher NRM. We conducted a multicenter, phase 2 study using natalizumab, a humanized monoclonal antibody that blocks T-cell trafficking to the GI tract through the \u03b14 subunit of \u03b14\u03b27 integrin, combined with corticosteroids as primary treatment for patients with new onset AA2\/3 GVHD. Seventy-five patients who were evaluable were enrolled and treated; 81% received natalizumab within 2\u00a0days of starting corticosteroids. Therapy was well tolerated with no treatment emergent adverse events in &amp;gt;10% of patients. Outcomes for patients treated with natalizumab plus corticosteroids were compared with 150 well-matched controls from the MAGIC database whose primary treatment was corticosteroids alone. There were no significant differences in overall or complete response between patients treated with natalizumab plus corticosteroids and those treated with corticosteroids alone (60% vs 58%; P\u00a0= .67% and 48% vs 48%; P\u00a0= 1.0, respectively) including relevant subgroups. There were also no significant differences in NRM or overall survival at 12\u00a0months in patients treated with natalizumab plus corticosteroids compared with controls treated with corticosteroids alone (38% vs 39%; P\u00a0= .80% and 46% vs 54%; P\u00a0= .48, respectively). In this multicenter biomarker\u2013based phase 2 study, natalizumab combined with corticosteroids failed to improve outcome of patients with newly diagnosed high-risk GVHD. This trial was registered at www.clinicaltrials.gov as # NCT02133924.<\/jats:p>","DOI":"10.1182\/bloodadvances.2023009853","type":"journal-article","created":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T15:23:59Z","timestamp":1694532239000},"page":"5189-5198","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":26,"title":["Phase 2 study of natalizumab plus standard corticosteroid treatment for high-risk acute graft-versus-host disease"],"prefix":"10.1182","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8226-471X","authenticated-orcid":false,"given":"Monzr M.","family":"Al Malki","sequence":"first","affiliation":[{"name":"1Hematology\/Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaitlyn","family":"London","sequence":"additional","affiliation":[{"name":"2The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janna","family":"Baez","sequence":"additional","affiliation":[{"name":"2The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6825-9340","authenticated-orcid":false,"given":"Yu","family":"Akahoshi","sequence":"additional","affiliation":[{"name":"2The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5841-4105","authenticated-orcid":false,"given":"William J.","family":"Hogan","sequence":"additional","affiliation":[{"name":"3Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Etra","sequence":"additional","affiliation":[{"name":"2The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Choe","sequence":"additional","affiliation":[{"name":"4Division of Hematology, James Cancer Center, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1125-4060","authenticated-orcid":false,"given":"Elizabeth","family":"Hexner","sequence":"additional","affiliation":[{"name":"5Blood and Marrow Transplantation Program, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0649-1915","authenticated-orcid":false,"given":"Amelia","family":"Langston","sequence":"additional","affiliation":[{"name":"6Winship Cancer Institute, Emory University, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Abhyankar","sequence":"additional","affiliation":[{"name":"7Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9422-5766","authenticated-orcid":false,"given":"Doris M.","family":"Ponce","sequence":"additional","affiliation":[{"name":"8Division of Hematology\/Oncology, Department of Medicine, Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7994-8974","authenticated-orcid":false,"given":"Zachariah","family":"DeFilipp","sequence":"additional","affiliation":[{"name":"9Hematopoietic Cell Transplant and Cellular Therapy Program, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie L.","family":"Kitko","sequence":"additional","affiliation":[{"name":"10Pediatric Stem Cell Transplant Program, Vanderbilt University Medical Center, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7166-9308","authenticated-orcid":false,"given":"Kehinde","family":"Adekola","sequence":"additional","affiliation":[{"name":"11Division of Hematology\/Oncology, Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Reshef","sequence":"additional","affiliation":[{"name":"12Blood and Marrow Transplantation, Columbia University Medical Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Ayuk","sequence":"additional","affiliation":[{"name":"13Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Capellini","sequence":"additional","affiliation":[{"name":"2The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantiya","family":"Chanswangphuwana","sequence":"additional","affiliation":[{"name":"14Department of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Eder","sequence":"additional","affiliation":[{"name":"15Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilbert","family":"Eng","sequence":"additional","affiliation":[{"name":"2The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2481-3933","authenticated-orcid":false,"given":"Isha","family":"Gandhi","sequence":"additional","affiliation":[{"name":"2The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Grupp","sequence":"additional","affiliation":[{"name":"16Division of Oncology, The Children\u2019s Hospital of Philadelphia, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigrun","family":"Gleich","sequence":"additional","affiliation":[{"name":"17Department of Hematology and Oncology, Internal Medicine III, University of Regensburg, Regensburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernst","family":"Holler","sequence":"additional","affiliation":[{"name":"17Department of Hematology and Oncology, Internal Medicine III, University of Regensburg, Regensburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora Rebeka","family":"Javorniczky","sequence":"additional","affiliation":[{"name":"18Department of Medicine I, Medical Center - University of Freiburg, Faculty of Medicine, Albert Ludwigs University, Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stelios","family":"Kasikis","sequence":"additional","affiliation":[{"name":"2The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Kowalyk","sequence":"additional","affiliation":[{"name":"2The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Morales","sequence":"additional","affiliation":[{"name":"2The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umut","family":"\u00d6zbek","sequence":"additional","affiliation":[{"name":"19Department of Population Health Science and Policy, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolf","family":"R\u00f6sler","sequence":"additional","affiliation":[{"name":"20Department of Internal Medicine 5, University Hospital Erlangen, Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5274-1749","authenticated-orcid":false,"given":"Nikolaos","family":"Spyrou","sequence":"additional","affiliation":[{"name":"2The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Yanik","sequence":"additional","affiliation":[{"name":"21Blood and Marrow Transplant Program, Michigan Medicine, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Young","sequence":"additional","affiliation":[{"name":"2The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9554-1058","authenticated-orcid":false,"given":"Yi-Bin","family":"Chen","sequence":"additional","affiliation":[{"name":"9Hematopoietic Cell Transplant and Cellular Therapy Program, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9082-0680","authenticated-orcid":false,"given":"Ryotaro","family":"Nakamura","sequence":"additional","affiliation":[{"name":"1Hematology\/Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James L. M.","family":"Ferrara","sequence":"additional","affiliation":[{"name":"2The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5611-7828","authenticated-orcid":false,"given":"John E.","family":"Levine","sequence":"additional","affiliation":[{"name":"2The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,9,12]]},"reference":[{"issue":"22","key":"2023091215235276800_bib1","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMra1609337","article-title":"Acute graft-versus-host disease - biologic process, prevention, and therapy","volume":"377","author":"Zeiser","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"2023091215235276800_bib2","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.bbmt.2015.01.001","article-title":"A\u00a0refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality","volume":"21","author":"MacMillan","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2023091215235276800_bib3","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/S2352-3026(14)00035-0","article-title":"A\u00a0prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study","volume":"2","author":"Levine","year":"2015","journal-title":"Lancet Haematol"},{"issue":"3","key":"2023091215235276800_bib4","doi-asserted-by":"crossref","first-page":"e89798","DOI":"10.1172\/jci.insight.89798","article-title":"An early-biomarker algorithm predicts lethal graft-versus-host disease and survival","volume":"2","author":"Hartwell","year":"2017","journal-title":"JCI Insight"},{"issue":"23","key":"2023091215235276800_bib5","doi-asserted-by":"crossref","first-page":"4034","DOI":"10.1182\/bloodadvances.2019000791","article-title":"The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host disease","volume":"3","author":"Srinagesh","year":"2019","journal-title":"Blood Adv"},{"issue":"4","key":"2023091215235276800_bib6","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.4049\/jimmunol.174.4.2343","article-title":"L-selectin, alpha 4 beta 1, and alpha 4 beta 7 integrins participate in CD4+ T cell recruitment to chronically inflamed small intestine","volume":"174","author":"Rivera-Nieves","year":"2005","journal-title":"J\u00a0Immunol"},{"issue":"11","key":"2023091215235276800_bib7","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1182\/blood-2009-12-259432","article-title":"Concurrent visualization of trafficking, expansion, and activation of T lymphocytes and T-cell precursors in\u00a0vivo","volume":"116","author":"Na","year":"2010","journal-title":"Blood"},{"issue":"3","key":"2023091215235276800_bib8","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1182\/blood-2005-02-0509","article-title":"In\u00a0vivo analyses of early events in acute graft-versus-host disease reveal sequential infiltration of T-cell subsets","volume":"106","author":"Beilhack","year":"2005","journal-title":"Blood"},{"issue":"1","key":"2023091215235276800_bib9","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/nm.2597","article-title":"Recipient nonhematopoietic antigen-presenting cells are sufficient to induce lethal acute graft-versus-host disease","volume":"18","author":"Koyama","year":"2011","journal-title":"Nat Med"},{"issue":"5","key":"2023091215235276800_bib10","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.immuni.2019.08.011","article-title":"MHC class II antigen presentation by the intestinal epithelium initiates graft-versus-host disease and is influenced by the microbiota","volume":"51","author":"Koyama","year":"2019","journal-title":"Immunity"},{"issue":"24","key":"2023091215235276800_bib11","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1182\/blood.2019000823","article-title":"The primacy of gastrointestinal tract antigen-presenting cells in lethal graft-versus-host disease","volume":"134","author":"Koyama","year":"2019","journal-title":"Blood"},{"issue":"2","key":"2023091215235276800_bib12","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1056\/NEJMoa1201248","article-title":"Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease","volume":"367","author":"Reshef","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"2023091215235276800_bib13","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.bbmt.2018.11.013","article-title":"Safety and effectiveness of vedolizumab in patients with steroid-refractory gastrointestinal acute graft-versus-host disease: a retrospective record review","volume":"25","author":"Fl\u00f8isand","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"2023091215235276800_bib14","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/s41409-018-0364-5","article-title":"Anti-\u03b14\u03b27 integrin monoclonal antibody (vedolizumab) for the treatment of steroid-resistant severe intestinal acute graft-versus-host disease","volume":"54","author":"Danylesko","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"2023091215235276800_bib15","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1038\/s41409-020-01049-0","article-title":"Phase II trial of natalizumab with corticosteroids as initial treatment of gastrointestinal acute graft-versus-host disease","volume":"56","author":"Kekre","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"2023091215235276800_bib16","first-page":"97","article-title":"Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue","volume":"151","author":"Briskin","year":"1997","journal-title":"Am J Pathol"},{"issue":"7","key":"2023091215235276800_bib17","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.4049\/jimmunol.152.7.3282","article-title":"Role of alpha 4-integrins in lymphocyte homing to mucosal tissues in\u00a0vivo","volume":"152","author":"Hamann","year":"1994","journal-title":"J\u00a0Immunol"},{"issue":"9","key":"2023091215235276800_bib18","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.bbmt.2009.05.003","article-title":"Up-regulation of alpha4beta7 integrin on peripheral T cell subsets correlates with the development of acute intestinal graft-versus-host disease following allogeneic stem cell transplantation","volume":"15","author":"Chen","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"2023091215235276800_bib19","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/bmt.2012.191","article-title":"Expression of \u03b14\u03b27 integrin on memory CD8(+) T cells at the presentation of acute intestinal GVHD","volume":"48","author":"Chen","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"2023091215235276800_bib20","first-page":"38","article-title":"Natalizumab: overview of its pharmacology and safety","volume":"7","author":"Baker","year":"2007","journal-title":"Rev Gastroenterol Disord"},{"issue":"24","key":"2023091215235276800_bib21","doi-asserted-by":"crossref","first-page":"6098","DOI":"10.1182\/bloodadvances.2020003336","article-title":"Biomarker-guided preemption of steroid-refractory graft-versus-host disease with \u03b1-1-antitrypsin","volume":"4","author":"Gergoudis","year":"2020","journal-title":"Blood Adv"},{"issue":"12","key":"2023091215235276800_bib22","doi-asserted-by":"crossref","first-page":"3707","DOI":"10.1182\/bloodadvances.2022007296","article-title":"Assessment of systemic and gastrointestinal tissue damage biomarkers for GVHD risk stratification","volume":"6","author":"Etra","year":"2022","journal-title":"Blood Adv"},{"issue":"1","key":"2023091215235276800_bib23","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","article-title":"International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai Acute GVHD International Consortium","volume":"22","author":"Harris","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"20","key":"2023091215235276800_bib24","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1093\/jnci\/djn326","article-title":"Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design","volume":"100","author":"Pepe","year":"2008","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"1","key":"2023091215235276800_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1214\/09-STS313","article-title":"Matching methods for causal inference: a review and a look forward","volume":"25","author":"Stuart","year":"2010","journal-title":"Stat Sci"},{"issue":"3","key":"2023091215235276800_bib26","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1214\/aos\/1176350951","article-title":"A\u00a0class of K-Sample tests for comparing the cumulative incidence of a competing risk","volume":"16","author":"Gray","year":"1988","journal-title":"Ann Stat"},{"key":"2023091215235276800_bib27","unstructured":"BMT CTN. BMT CTN. Appendix 4-A\n          . Severity grading table and recurrence interval definitions. Technical manual of procedures; 2013. Accessed 6 May 2020. https:\/\/webemmescom\/study\/bmt2\/public\/Definition\/Severity%20Grading_Recurrence%20Intervalpdf."},{"issue":"11","key":"2023091215235276800_bib28","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S1474-4422(17)30282-X","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies","volume":"16","author":"Ho","year":"2017","journal-title":"Lancet Neurol"},{"issue":"10","key":"2023091215235276800_bib29","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1007\/s00277-018-3385-7","article-title":"Outcome of gastrointestinal graft-versus-host disease according to the treatment response","volume":"97","author":"Tamaki","year":"2018","journal-title":"Ann Hematol"},{"issue":"11","key":"2023091215235276800_bib30","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.1182\/bloodadvances.2021006220","article-title":"Prediction of outcomes after second-line treatment for acute graft-versus-host disease","volume":"6","author":"Vo","year":"2022","journal-title":"Blood Adv"},{"issue":"5","key":"2023091215235276800_bib31","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1053\/j.gastro.2007.03.024","article-title":"Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial","volume":"132","author":"Targan","year":"2007","journal-title":"Gastroenterology"},{"issue":"4","key":"2023091215235276800_bib51","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/sj.bmt.1705435","article-title":"Steroid myopathy in patients with acute graft-versus-host disease treated with high-dose steroid therapy","volume":"38","author":"Lee","year":"2006","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"2023091215235276800_bib32","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1038\/s41409-018-0094-8","article-title":"Vedolizumab for treatment of steroid-refractory lower gastrointestinal acute graft-versus-host disease","volume":"53","author":"Coltoff","year":"2018","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"2023091215235276800_bib33","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/j.bbmt.2017.05.028","article-title":"Lessons learned from early experiences with vedolizumab for steroid-refractory acute graft- versus-host disease with gastrointestinal involvement","volume":"23","author":"Bukauskas","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2023091215235276800_bib34","doi-asserted-by":"crossref","first-page":"272.e271","DOI":"10.1016\/j.jtct.2020.12.011","article-title":"Vedolizumab for steroid refractory lower gastrointestinal tract hraft-versus-host disease","volume":"27","author":"Mehta","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"2023091215235276800_bib35","doi-asserted-by":"crossref","first-page":"1025350","DOI":"10.3389\/fimmu.2022.1025350","article-title":"Vedolizumab for acute gastrointestinal graft-versus-host disease: a systematic review and meta-analysis","volume":"13","author":"Li","year":"2022","journal-title":"Front Immunol"},{"issue":"23","key":"2023091215235276800_bib36","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1182\/bloodadvances.2019000893","article-title":"Vedolizumab for prevention of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation","volume":"3","author":"Chen","year":"2019","journal-title":"Blood Adv"},{"issue":"20","key":"2023091215235276800_bib37","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"366","author":"Bloomgren","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"2023091215235276800_bib38","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1093\/cid\/civ285","article-title":"Acute gastrointestinal graft-vs-host disease is associated with increased enteric bacterial bloodstream infection density in pediatric allogeneic hematopoietic cell transplant recipients","volume":"61","author":"Levinson","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"1","key":"2023091215235276800_bib39","doi-asserted-by":"crossref","first-page":"e13217","DOI":"10.1111\/tid.13217","article-title":"Severity of acute gastrointestinal graft-vs-host disease is associated with incidence of bloodstream infection after adult allogeneic hematopoietic stem cell transplantation","volume":"22","author":"Modi","year":"2020","journal-title":"Transpl Infect Dis"},{"issue":"10","key":"2023091215235276800_bib40","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1182\/blood-2009-09-242784","article-title":"Graft-versus-host disease: regulation by microbe-associated molecules and innate immune receptors","volume":"115","author":"Penack","year":"2010","journal-title":"Blood"},{"issue":"2","key":"2023091215235276800_bib41","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.bbmt.2014.10.003","article-title":"Blood and marrow transplant clinical trials network state of the science symposium 2014","volume":"21","author":"Appelbaum","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"2023091215235276800_bib42","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1182\/bloodadvances.2021005847","article-title":"Posttransplant cyclophosphamide for prevention of graft-versus-host disease: results of the prospective randomized HOVON-96 trial","volume":"6","author":"Broers","year":"2022","journal-title":"Blood Adv"},{"issue":"3","key":"2023091215235276800_bib43","doi-asserted-by":"crossref","first-page":"e132","DOI":"10.1016\/S2352-3026(18)30221-7","article-title":"Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203)","volume":"6","author":"Bolanos-Meade","year":"2019","journal-title":"Lancet Haematol"},{"issue":"17","key":"2023091215235276800_bib44","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1200\/JCO.20.01086","article-title":"Phase II trial of costimulation blockade with abatacept for prevention of acute GVHD","volume":"39","author":"Watkins","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"2023091215235276800_bib45","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1038\/s41409-021-01274-1","article-title":"Acute graft-versus-host disease is the foremost cause of late nonrelapse mortality","volume":"56","author":"Ramdial","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"2023091215235276800_bib46","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/sj.bmt.1705140","article-title":"Cause of death after allogeneic haematopoietic stem cell transplantation (HSCT) in early leukaemias: an EBMT analysis of lethal infectious complications and changes over calendar time","volume":"36","author":"Gratwohl","year":"2005","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"2023091215235276800_bib47","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1080\/03007995.2018.1551193","article-title":"Mortality, length of stay and costs associated with acute graft-versus-host disease during hospitalization for allogeneic hematopoietic stem cell transplantation","volume":"35","author":"Yu","year":"2019","journal-title":"Curr Med Res Opin"},{"issue":"7","key":"2023091215235276800_bib48","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1007\/s00520-019-05124-1","article-title":"Effect of the severity of acute graft-versus-host disease on physical function after allogeneic hematopoietic stem cell transplantation","volume":"28","author":"Hamada","year":"2020","journal-title":"Support Care Cancer"},{"issue":"3","key":"2023091215235276800_bib49","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1359\/jbmr.1999.14.3.342","article-title":"Mechanisms of bone loss following allogeneic and autologous hemopoietic stem cell transplantation","volume":"14","author":"Ebeling","year":"1999","journal-title":"J\u00a0Bone Miner Res"},{"issue":"15","key":"2023091215235276800_bib50","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1007\/s40265-014-0282-9","article-title":"Systemic glucocorticoid therapy: a review of its metabolic and cardiovascular adverse events","volume":"74","author":"Fardet","year":"2014","journal-title":"Drugs"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/17\/5189\/2077025\/blooda_adv-2023-009853-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/17\/5189\/2077025\/blooda_adv-2023-009853-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T15:24:17Z","timestamp":1694532257000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/17\/5189\/496056\/Phase-2-study-of-natalizumab-plus-standard"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,12]]},"references-count":51,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2023,9,12]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023009853","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,12]]}}}